ZEVRA THERAPEUTICS, INC. (ZVRA): Submission of Matters to a Vote of Security Holders
ZEVRA THERAPEUTICS, INC. (ZVRA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. zvra-20260604 false 0001434647 0001434647 2026-06-04 2026-06-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 __________________________________________________________________________________________ FORM 8-K ____________________________________________
How this was made
The 30-second read
Why it matters
Two Class II directors were elected and Ernst & Young LLP was ratified, while the charter amendment to declassify the board did not receive the required supermajority.
Market read
Governance vote results are disclosed; only the failed declassification amendment could modestly influence governance sentiment.
What to watch
Traders may overreact to Proposal 3’s failure; the more actionable near-term items would be any subsequent proxy/board actions or future financing/clinical catalysts, none of which are disclosed here.
Background
The article is an SEC Form 8-K (Item 5.07) summarizing votes from Zevra Therapeutics’ June 4, 2026 annual meeting, referencing a proxy filed April 20, 2026.
Ticker impact
Zevra’s 8-K reports the June 4, 2026 annual meeting vote results, including director elections and a failed board declassification proposal.
Likely limited immediate price impact; any effect would be indirect via governance/overhang rather than fundamentals.
The filing is a routine post-meeting disclosure with no new financial guidance, clinical, or regulatory catalyst; the only notable item is Proposal 3 failing to reach the required 66 2/3% threshold.
Market effects
Minimal; this is company-specific governance rather than a sector-wide regulatory/clinical development.
Minimal; no regional macro or cross-listed event described.
Minimal; no international transaction or global regulatory action mentioned.
Counterpoint
The failed declassification vote may be a one-off shareholder preference rather than a durable governance risk, limiting any downside follow-through.
Key entities
- issuerZevra Therapeutics, Inc.
Nasdaq-listed company whose annual meeting vote outcomes are reported.
- director_nomineeDouglas W. Calder
Elected Class II director at the annual meeting (Proposal 1).
- director_nomineeCorey Watton
Elected Class II director at the annual meeting (Proposal 1).
- auditorErnst & Young LLP
Ratified as independent registered public accounting firm for fiscal year ending Dec. 31, 2026 (Proposal 2).
